Cambridge Innovation Capital Fund III

Cambridge Innovation Capital

cb Email

Status

ACTIVE

Global HQ

Cambridge, United Kingdom

Countries of investment

United Kingdom

Investment stages

Seed
Series A
Series B
Series C
Growth

Industries

Life Sciences
DeepTech
Quantum
AI
Semiconductors
Biotech
Advanced Therapeutics
MedTech

About
Cambridge Innovation Capital is a Cambridge-based venture capital firm focused on backing Cambridge University spinouts and UK deep tech companies. Their focus spans life sciences, deep tech, quantum, AI, and semiconductors across the United Kingdom. The firm supports university spinout founders from seed through growth stages.

Min check size: $2M
Max check size: $15M
Fund size: Unlock
NPS: Unlock

Investment Thesis

Cambridge Innovation Capital is a seed to growth stage venture capital firm deploying capital across life sciences, deep tech, quantum, AI, and semiconductor sectors. They invest as one of the UK's most active investors in Cambridge University spinouts and other UK deep tech companies with world-class science and engineering foundations. The firm differentiates itself through preferred partnership with the University of Cambridge, £500M+ AUM, and deep network across the Cambridge innovation ecosystem.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

Founded in 2013, based in Cambridge with dedicated commercialization partnership with the University of Cambridge. Leadership includes Andrew Williamson (Managing Partner and Chief Investment Officer), Peter Keen (Managing Partner), and additional Partners across life sciences and deep tech. Team of 20+ investment professionals. Manages over £500M AUM across multiple funds with backing from institutional investors, family offices, and University of Cambridge. Portfolio includes Nu Quantum, Riverlane, Bicycle Therapeutics (IPO), Kymab (acquired by Sanofi for $1.45B), Congenica, Prowler, Featurespace, PragmatIC Semiconductor, Pockit, and Wayve. Preferred partner to the University of Cambridge for commercialization, with unique access to Cambridge University spinouts and world-class scientific research. Recently expanded focus to include AI, quantum, and semiconductors alongside its historical life sciences strength.